NRx Pharmaceuticals, Inc. NRXP
3.00
(0.03)
(0.99%)
as of 25 Sep
- Market cap
- $131.2M
- P/E
- 0.0×
Follow NRXP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 131.22% | 125.92% | 146.18% | 170.77% |
+8 more TTM periods Free account |
|
| (120.41%) | (251.78%) | (344.70%) | (391.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
618.36% | 139.78% | 145.86% | 133.19% | |
Average Days of Receivables |
22.15 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.55) | (0.46) | (0.66) | (0.56) | |
Free Cash Flow |
(20.67) | (14.93) | (14.11) | (12.50) | |
Capital Expenditures |
(0.90) | — | — | — | |
Piotroski F-Score |
6.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(73.43%) | 210.15% | 173.37% | 146.85% | |
Accounts Receivable Turnover |
32.02 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.53 | 0.26 | 0.12 | 0.02 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
634.06 | 1,410.93 | 3,068.01 | 15,384.21 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
159.43% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
469.45% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
12.93% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.61 | 0.49 | 0.33 | |
Depreciation/Fixed assets |
0.52 | 1.19 | 2.30 | 0.68 | |
Capex/Depreciation |
(1.86) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.09 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.53) | (0.46) | (0.66) | (0.56) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | — | — | — | |
Net Profit Margin |
(691.78%) | 0.00% | 0.00% | 0.00% |
Columns are period end dates